Funder
NIHR, Biomedical Research Centre, South London and Maudsley NHS Foundtion Trust and King's College, London
JMAS Sim Fellowship, Royal College of Physicians, Edinburgh
Publisher
Springer Science and Business Media LLC
Subject
Biological Psychiatry,Psychiatry and Mental health
Reference61 articles.
1. Alda M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry. 2015;20(6):661–70.
2. Allergan Announces FDA Acceptance of Supplemental New Drug Application For VRAYLAR® (cariprazine) [Internet]. Allergan. Available from:
https://www.allergan.com/news/news/thomson-reuters/allergan-announces-fda-acceptance-of-supplemental
.
3. Ashok AH, Marques TAR, Jauhar S, Nour M, Goodwin GM, Young A, et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry. 2017;22(5):666–79.
4. Bauer M, Andreassen OA, Geddes JR, Kessing LV, Lewitzka U, Schulze TG, et al. Areas of uncertainties and unmet needs in bipolar disorders: clinical and research perspectives. Lancet Psychiatry. 2018;5(11):930–9.
5. Berk M, Daglas R, Dandash O, Yücel M, Henry L, Hallam K, et al. Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial. Br J Psychiatry. 2017.
https://doi.org/10.1192/bjp.bp.116.186833
.
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献